An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Completed · Phase 2

Conditions studied: Type 2 Diabetes Mellitus

In brief

Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.

Key facts

Study ID

NCT02435277

Run by

NuSirt Biopharma

People needed

50

Starts

2014-10-01

Expected to finish

2016-01-01

Last updated by the study team

2018-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations
• Is male, or female and, if female, meets all of the following criteria:
• Not breastfeeding
• Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit [β-hCG]) at Screening (Visit 1) (not required for hysterectomized females)
• If of childbearing potential (including perimenopausal women who have had a menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study.
• Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from the study.
• Is undesirable as a study participant as judged by the investigator (e.g., exhibited poor compliance during Study NS-0100-01)
• Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:
• Lipid-lowering agents
• Anti-hypertensive medications
• Thyroid replacement therapy
• Non-steroidal anti-inflammatory agents
• Is expected to require or undergo treatment with any of the following medications:
• Antidiabetes medications (with the exception of study medication [i.e., metformin])
• Oral or parenteral steroids.

Where it is running

• Catalina Research Institute — Chino, California, United States
• Palm Beach Research — Palm Beach, Florida, United States
• Meridien Research — Tampa, Florida, United States
• River Birch Research Alliance — Blue Ridge, Georgia, United States
• Meridian Research — Savannah, Georgia, United States
• Streling Research Group — Cincinnati, Ohio, United States
• Medical Research South — Charleston, South Carolina, United States
• Meharry Medical College — Nashville, Tennessee, United States
• Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.